As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Overall US COVID-19 Vaccine administration and vaccine equity data at county level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

NOTE: As of 2/16/2023, this table is not being updated. For data on COVID-19 updated (bivalent) booster coverage by town please to go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh.

This table shows the number and percent of residents of each CT town that have initiated COVID-19 vaccination, are fully vaccinated and who have received additional dose 1.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut).

Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. People for whom an address is not currently available are shown in this table as “Address pending validation”. Out-of-state residents vaccinated by CT providers are excluded from the table.

Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated when records for an individual cannot be linked because of differences in how names or date of birth are reported.

Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town.

SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Town" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/pdqi-ds7f) , which will not be updated after 4/15/2021. A breakdown of vaccinations by town and by age group is also available here: https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw .

As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

NOTE: As of 4/15/2021, this dataset will no longer be updated and will be replaced by two new datasets: 1) "COVID-19 Vaccinations by Town" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/x7by-h8k4) and "COVID-19 Vaccinations by Town and Age Group" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw). A summary of COVID-19 vaccination coverage in Connecticut by town. Records without an address could not be included in town vaccine coverage estimates. Total population estimates are based on 2019 data. A person who has received one dose of any vaccine is considered to have received at least one dose. A person is considered fully vaccinated if they have received 2 doses of the Pfizer or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The number with At Least One Dose and the number Fully Vaccinated add up to more than the total number of doses because people who received the Johnson & Johnson vaccine fit into both categories. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

Parameters related to vaccine efficacy.

Percentages of children and pregnant women who have received recommended vaccines, by target population and vaccine/antigen covering results from the 2011, 2013, 2015, 2017, 2019, and 2021 cycles of the Childhood National Immunization Coverage Survey.

As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

As of September 24, 2023, around 50 million people in Italy have completed the regular vaccination cycle against COVID-19, corresponding to roughly 85 percent of the total population. In the age group 80 years and older, the one most vulnerable to the virus, this figure reached almost 96 percent. A vaccine for kids under 12 years of age became available only in December 2021. To build a better protection against the virus over time, the Italian authorities started administering a third vaccine dose during autumn 2021, and a fourth dose in spring 2022. So far, roughly three out of four Italians over 12 years of age have received a booster shot. More statistics and facts about the virus in Italy are available here.For a global overview on the various COVID-19 vaccines' development and distribution, visit Statista's Facts and Figures on the topic.

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

As part of the National Immunization Strategy objectives for 2016-2021, vaccination coverage goals and vaccine preventable disease reduction targets were set based on international standards and best practices. The goals and targets are consistent with Canada's commitment to World Health Organization (WHO) disease elimination targets and Global Vaccine Action Plan, while reflecting the Canadian context.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Cattle Vaccines Market Size And Forecast

Cattle Vaccines Market size was valued at USD 13.07 Billion in 2023 and is projected to reach USD 21.33 Billion by 2031, growing at a CAGR of 6.32% during the forecast period 2024-2031.

Global Cattle Vaccines Market Drivers

The market drivers for the Cattle Vaccines Market can be influenced by various factors. These may include:

Growing Rate Of Diseases In Cattle: Effective vaccines are in high demand in order to protect cattle from infectious diseases such as brucellosis, foot-and-mouth disease, and viral diarrhoea in cows.

Growing Requirement For Animal-Based Protein: The growing number of people on the planet has increased demand for dairy and meat products, which calls for robust herds of cattle. In order to prevent disease outbreaks and maintain constant production, this demand drives the need for vaccines.

Technological Developments In Vaccines: The creation of more potent and effective vaccinations, particularly those that provide extended immunity and broad-spectrum protection, has been facilitated by advancements in immunology and biotechnology. These developments support market expansion.

Governmental Proposals And Assistance: Worldwide, a large number of governments carry out immunisation campaigns and offer financial assistance or subsidies for veterinary services, which includes vaccinations for cattle. These programmes aid in the prevention of livestock illnesses and promote market expansion.

Raising Preventive Healthcare Awareness And Adoption: Vaccination rates are rising as a result of farmers and livestock owners’ growing awareness of the advantages of preventive care for cattle. This is largely due to the education and outreach initiatives that veterinary businesses and organisations run.

Growth Of The Meat And Dairy Industries: The need for cow vaccinations is driven by the expansion of the meat and dairy industries, particularly in emerging economies. The necessity of keeping sizable, healthy herds grows as these sectors develop.

Livestock Diseases’ Effects On The Economy: Cattle disease outbreaks can have serious economic repercussions, such as reduced production, trade restrictions, and animal losses. Vaccination is a reasonably priced way to reduce these dangers, which is fueling demand.

Creation Of Novel And Better Vaccines: New vaccinations with improved protection, fewer side effects, and simpler administration are introduced as a result of ongoing research and development efforts, which has a favourable effect on market expansion.

Standards And Regulations: Vaccine usage is encouraged by strict laws and guidelines pertaining to the health and safety of animals. Adherence to these standards is crucial for the commerce and export of livestock, hence promoting the implementation of vaccination campaigns.

Growing The Population Of Livestock: The number of animals worldwide is increasing, especially in emerging nations where raising cattle is a major source of income. More vaccinations are required to prevent and manage diseases in a greater population of cattle.

Household Pulse Survey (HPS): HPS is a rapid-response survey of adults ages ≥18 years led by the U.S. Census Bureau, in partnership with seven other federal statistical agencies, to measure household experiences during the COVID-19 pandemic. Detailed information on probability sampling using the U.S. Census Bureau’s Master Address File, questionnaires, response rates, and bias assessment is available on the Census Bureau website (https://www.census.gov/data/experimental-data-products/household-pulse-survey.html).

Data from adults age ≥18 years are collected by 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). Data are weighted to represent total persons age 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Data from adults age ≥18 years are collected by 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). For more information on this survey, see https://www.census.gov/programs-surveys/household-pulse-survey.html.

Data are weighted to represent total persons age 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Responses in the Household Pulse Survey (https://www.census.gov/programs-surveys/household-pulse-survey.html) are self-reported. Estimates of vaccination coverage may differ from vaccine administration data reported at COVID-19 Vaccinations in the United States (https://covid.cdc.gov/covid-data-tracker/#vaccinations).

Explore the top import markets for vaccines and discover key statistics on their import values. Learn about the growing global demand for vaccines and the role of key countries in meeting vaccination needs.

Summary statistics for outcome and explanatory variables.